Genentech
A Member of the Roche Group

Issue Date: July 26, 2016

Call for Grant Notification: Healthcare-Related Charitable Support

The Advocacy Relations team at Genentech, a member of Roche Group, invites the non-profit community to submit applications for grants subject to the terms below. This Call for Grants Notification (CGN) provides public notice of the availability of funds in a general topic area for activities for which recognized needs exist.

Purpose: As part of our mission and commitment to philanthropy, Genentech supports non-profit organizations **focusing on patient education, patient services and advocacy.** The purpose of this CGN is to support initiatives focused on the patient and caregiver community. Support requests must be healthcare-related and consistent with therapeutic or technological area(s) in which Genentech and/or Roche is active. This CGN is intended to support initiatives that address broad cross-disease issues.

Notification: Genentech CGNs are made available through the online Genentech Funding Request System (gFRS) site (http://funding.gene.com). In addition, an email is distributed to registered gFRS users who have previously applied for healthcare-related charitable support. A WebEx detailing CGN funding priorities and the CGN application process will be available to those interested the week after posting on **Monday August 1, 2016**.

Eligibility Criteria: Applicants must be U.S-based and registered on the Genentech Funding Request System (gFRS). Each applicant's organization must be recognized by the IRS as a tax exempt, public charity under section 501(c)(3) of the Internal Revenue Code and must be located in the United States.

Geographical Scope: The programs and services **must be U.S.-based only.**

NEW! Submission Instructions for *Executive Summary*:

1. Applicants who meet the eligibility criteria and are interested in submitting a response to this CGN must first complete a brief ***Executive Summary*** through the following link or paste the URL (https://goo.gl/forms/chOzJiTlmhIDORtK2) into a new browser.
2. https://goo.gl/forms/chOzJiTlmhIDORtK2
   Deadline for Executive Summary submission will be Friday September 9, 2016 (11:59 Pacific Time).
   Note: Do not submit your initial application through gFRS.
3. By **Monday September 26, 2016**, a Genentech Grant Manager will contact (i.e. by email) those applicants whose Executive Summaries were selected for further review.
4. Those applicants who receive notifications of potential interest may then submit full grant proposal applications online through gFRS. Further instructions will be provided in the email notification. Deadline to submit full grant proposal will be **Monday October 3, 2016 (11:59 Pacific Time).**

Award Decision Date/Mechanism: Final approvals and denials for those who are selected to submit a full application in gFRS will be communicated via standard grant-submission means (i.e. email notifications) no later than **Monday November 21, 2016.** *There have been no pre-determined approvals. All submissions will be reviewed equally and thoroughly.*

Applicants should not respond to this CGN unless they have read and understood the terms, purpose and requests identified below. Applicants are expected to identify and address issues that are aligned to this CGN. Proposed projects with budgets between $20,000-100,000 will be considered; this CGN will fund up to five projects in total. Please note that Genentech cannot be the sole sponsor for any given project.

Genentech
A Member of the Roche Group

Topic and Funding Priorities	**Clinical Trial Recruitment** As part of our commitment to philanthropy, Genentech supports nonprofit organizations focusing on patient education, patient services and advocacy. The purpose of this CGN is to support initiatives focused on the patient and caregiver community. Support requests must be healthcare-related and consistent with therapeutic or technological area(s) in which Genentech and/or Roche is active. Types of programs and services considered as part of this CGN include, but are not limited to the following: Patient Services, Patient Outreach, Patient Education, Disease Education, Fundraisers, and Health Screenings.
Introduction and Background	Participation in clinical trials enables patients to gain access to investigational medicines and/or procedures that are not yet available to the public.[1,2] The rates of both clinical trial participation and survival are higher for children diagnosed with cancer, compared to adults diagnosed with cancer.[2] Doctors link the higher survival rate for children, in part, to the enrollment of patients in cancer clinical trials over many years.[2] Poor patient recruitment and retention in clinical trials is considered a major cause of drug development delays.[3,4] According to research conducted by the Tufts Center for the Study of Drug Development, while nine out of 10 clinical trials meet their patient enrollment goals, reaching those targets typically means that original trial timelines nearly double[4], ultimately increasing the time before a new drug becomes available to patients. Patient participation in clinical trials remains low in the U.S.[2,3,5,6] For example, less than five percent of eligible U.S. adults diagnosed with cancer participate in a clinical trial.[2,5] Enrollment among racial/ethnic minority, elderly, adolescent, and young adult populations in particular may not be adequate to study aspects of care unique to these populations.[6,7,8] Barriers to clinical trial participation exist at many levels, including patient-related, provider-related, and system-wide barriers.[6] Examples of patient-related barriers to clinical trial participation include, but are not limited to: • *Variable awareness and knowledge about clinical trials:* Although one third of American adults indicate that they would be very willing to participate in a cancer clinical trial if asked to do so[9], only 10% of cancer survivors report that they were aware of the possibility of clinical trial participation at the time of their diagnosis, and only 3% report participation in a clinical trial.[10] • *Attitude toward randomization or assignment to placebo:* Patients may hesitate to join clinical trials for fear that they will not receive efficacious treatment due to randomization to placebo.[11,12] This fear is well-documented in the oncology literature.[13,14] • *Misperceptions About Financial Burden:* Initial work by R. Comis indicated that misperceptions about financial burden of clinical trial participation may be an important barrier.[15] In a recent study of 1,755 trial-eligible patients who declined participation, cost considerations were important for a significant proportion of these patients.[15] Twenty-eight percent cited concerns about added cost, and 12% noted cost as the most important factor in their decision.[16]

- *Inconvenience of participating in a trial, including logistics and protocol considerations:* Protocol complexity is one of the most commonly cited patient-centered concerns that deter participation.[6] Likewise, logistics, such as driving distance, can also make participation challenging, especially among older, rural, and minority patients.[17,18]

Call for Grants Notice Requirements and Aim

Aim

The aim of this CGN is to support proposals that address patient/caregiver challenges related to clinical trial recruitment, specifically proposals that aim to raise patient awareness regarding clinical trials or support improved patient access to clinical trial information, such as initiatives that:

- Develop patient-friendly educational materials that provide accurate and balanced information about clinical trial participation.
- Develop awareness campaigns that target disease areas with limited or dispersed patient populations (e.g., rare disease).
- Educate racial/ethnic minority, elderly, adolescent, and/or young adult populations on clinical trial participation.
- Utilize digital platforms, social media and mobile technologies to facilitate enrollment in clinical trials and/or to enable remote participation, where appropriate.

Call for Grants Notice Requirements

Proposals should define the unmet need being addressed in the project and utilize evidence from internal (e.g., surveys of constituents, qualitative data from front-line staff) and external (e.g., consensus reports, peer-reviewed journal articles) data sources to help establish a clear view on the unmet need.

Successful applications will include patient-focused solutions to documented unmet needs through a project that includes: an innovative program or service, well-defined process and outcome evaluation metrics, and a conceptual plan for expansion and sustainability.

Out-of-the-box and non-traditional models of service delivery are encouraged. Applicants are also encouraged to utilize a collaborative approach to this effort and work with other organizations, though each application must be submitted by one single organization selected to represent the project for this CGN.

Additional Considerations: Grant requests must be submitted at least 60 days prior to the project / program start date. The following uploads are required to submit your application: W-9 Form / W-8BEN form, promotional materials and/or event advertising (if applicable), meeting agenda (if applicable) and detailed / itemized budget.

Genentech's Grant Decision-Making Policy: Please refer to the publicly available criteria, which can be found at http://funding.gene.com.

Terms and Conditions:

1. All grant applications received in response to this CGN will be reviewed in accordance with all Genentech policies and policy guidelines.

2. This CGN does not commit Genentech to award a grant or to pay any costs incurred in the preparation of a response to this request.
3. Genentech reserves the right to approve or deny any or all applications received as a result of this request or to cancel, in part or in its entirety, this CGN.
4. For compliance reasons, and in fairness to all applicants, all communications about this CGN must come exclusively to Genentech's department of Advocacy Relations. Failure to comply will automatically disqualify applicants.
5. Failure to follow instruction within this CGN may result in a denial.

Transparency: Genentech, at its sole discretion, has the right to disclose the details of funded healthcare related charitable support, including those that may be required by federal, state, and/or local laws and regulations. This disclosure may include, but shall not be limited to, details of the activity and the grant amount. The information may be disclosed to the public in a manner including, but not limited to, disclosure on the Genentech website.

References:

1. Darrow JJ, Sarpatwari A, Avorn J, Kesselheim AS. Practical, Legal, and Ethical Issues in Expanded Access to Investigational Drugs. *N Engl J Med.* 2015 Jan 15;372(3):279-86. http://www.ncbi.nlm.nih.gov/pubmed/25587952 (Accessed June 23, 2016)
2. American Society of Clinical Oncology. Cancer.Net: About Clinical Trials. http://www.cancer.net/navigating-cancer-care/how-cancer-treated/clinical-trials/about-clinical-trials (Accessed February 23, 2016) Substitute with Peer Reviewed Journal Article
3. U.S. Department of Health and Human Services. Examination of Clinical Trial Costs and Barriers for Drug Development. July 2014. https://aspe.hhs.gov/report/examination-clinical-trial-costs-and-barriers-drug-development (Accessed February 23, 2016)
4. Tufts Center for the Study of Drug Development. Impact Report: 89% of trials meet enrollment, but timelines slip, half of sites under-enroll. January/February 2013, Vol. 15 No. 1. http://csdd.tufts.edu/files/uploads/02_-_jan_15,_2013_-_recruitment-retention.pdf (Accessed March 29, 2016)
5. Institute of Medicine. A national cancer clinical trials system for the 21st century: Reinvigorating the NCI Cooperative Group Program. Washington, DC. The National Academies Press, 2010. http://www.nap.edu/download.php?record_id=12879 (Accessed March 29, 2016)
6. Denicoff AM, McCaskill-Stevens W, Grubbs SS, Bruinooge SS, Comis RL, Devine P, Dilts DM, Duff ME, Ford JG, Joffe S, Schapira L, Weinfurt KP, Michaels M, Raghavan D, Richmond ES, Zon R, Albrecht TL, Bookman MA, Dowlati A, Enos RA, Fouad MN, Good M, Hicks WJ, Loehrer PJ Sr, Lyss AP, Wolff SN, Wujcik DM, Meropol NJ. The National Cancer Institute-American Society of Clinical Oncology Cancer Trial Accrual Symposium: summary and recommendations. *J Oncol Pract.* 2013 Nov;9(6):267-76. http://www.ncbi.nlm.nih.gov/pubmed/24130252 (Accessed March 29, 2016)
7. Stewart JH, Bertoni AG, Staten JL, Levine EA, Gross CP. Participation in surgical oncology clinical trials: gender-, race/ethnicity-, and age-based disparities. *Ann Surg Oncol.* 2007 Dec;14(12):3328-34. http://www.ncbi.nlm.nih.gov/pubmed/17682824 (Accessed March 29, 2016)
8. Goss E, Lopez AM, Brown CL, Wollins DS, Brawley OW, Raghavan D. American society of clinical oncology policy statement: disparities in cancer care. *J Clin Oncol.* 2009 Jun 10;27(17):2881-5. http://www.ncbi.nlm.nih.gov/pubmed/19403885 (Accessed March 29, 2016)
9. Comis RL, Miller JD, Aldigé CR, Krebs L, Stoval E. Public attitudes toward participation in cancer clinical trials. *J Clin Oncol.* 2003 Mar 1;21(5):830-5. http://www.ncbi.nlm.nih.gov/pubmed/12610181 (Accessed March 29, 2016)

10. Comis RL, Miller JD, Colaizzi DD, Kimmel LG. Physician-related factors involved in patient decisions to enroll onto cancer clinical trials. *J Oncol Pract.* 2009 Mar;5(2):50-6. http://www.ncbi.nlm.nih.gov/pubmed/20856718 (Accessed March 29, 2016)
11. Mills EJ, Seely D, Rachlis B, Griffith L, Wu P, Wilson K, Ellis P, Wright JR. Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors. *Lancet Oncol.* 2006 Feb;7(2):141-8. http://www.ncbi.nlm.nih.gov/pubmed/16455478 (Accessed March 29, 2016)
12. Meropol NJ, Buzaglo JS, Millard J, Damjanov N, Miller SM, Ridgway C, Ross EA, Sprandio JD, Watts P. Barriers to clinical trial participation as perceived by oncologists and patients. *J Natl Compr Canc Netw.* 2007 Sep;5(8):655-64. http://www.ncbi.nlm.nih.gov/pubmed/17927923 (Accessed March 29, 2016)
13. National Cancer Institute. Placebos in Cancer Clinical Trials. Updated: Nov 2, 2012. http://www.cancer.gov/about-cancer/treatment/clinical-trials/what-are-trials/placebo (Accessed March 29, 2016)
14. Coalition of Cancer Cooperative Groups. Myths & Facts About Cancer Clinical Trials. http://www.cancertrialshelp.org/Icare_content/icMainContent.aspx?intAppMode=7 (Accessed March 29, 2016)
15. Comis RL, Aldigé CR, Stovall EL, Krebs LU, Risher PJ, Taylor HJ. A quantitative survey of public attitudes towards cancer clinical trials. Spring 2000. http://www.cancertrialshelp.org/CTHpdf/308-9.pdf (Accessed March 29, 2016)
16. Weckstein DJ, Thomas CA, Emery IF, Shea BF, Fleury A, White ME, Chase E, Robinson C, Frazier S, Pilar C. Assessment of perceived cost to the patient and other barriers to clinical trial participation. *J Oncol Pract.* 2011 Sep;7(5):330-3. http://www.ncbi.nlm.nih.gov/pubmed/22211132 (Accessed March 29, 2016)
17. Basche M, Barón AE, Eckhardt SG, Balducci L, Persky M, Levin A, Jackson N, Zeng C, Vranas P, Steiner JF. Barriers to enrollment of elderly adults in early-phase cancer clinical trials. *J Oncol Pract.* 2008 Jul;4(4):162-8. http://www.ncbi.nlm.nih.gov/pubmed/20856765 (Accessed March 29, 2016)
18. Virani S, Burke L, Remick SC, Abraham J. Barriers to recruitment of rural patients in cancer clinical trials. *J Oncol Pract.* 2011 May;7(3):172-7. http://www.ncbi.nlm.nih.gov/pubmed/21886499 (Accessed March 29, 2016)